Non disponible en dehors du Royaume-Uni et de l'Irlande
Biochem/physiol Actions
Reversible: no
Product does not compete with ATP.
Target IC50: 100 µM and 10 µM against insulin receptor tyrosine kinase and insulin-stimulated glucose oxidation in isolated rat adipocytes, respectively
Primary Targettyrosine kinase
Cell permeable: yes
General description
A cell-permeable analog of HNMPA. Inhibits insulin receptor tyrosine kinase (IC50 = 100 mM) and insulin-stimulated glucose oxidation in isolated rat adipocytes (IC50 = 10 µM). Also reported to inhibit tyrosine autophosphorylation of the human insulin receptor (IC50 = 200 µM). It has no effect on PKA (at concentrations up to 1 mM) or PKC (at concentrations up to 420 µM).
A cell-permeable analog of HNMPA that yields the parent compound upon cleavage by cytosolic esterases. Inhibits insulin receptor tyrosine kinase (IC50 = 100 µM) and insulin-stimulated glucose oxidation in isolated rat adipocytes (IC50 = 10 µM). Also reported to inhibit tyrosine autophosphorylation of the human insulin receptor (IC50 = 200 µM).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Baltensperger, K., et al. 1992. Proc. Natl. Acad. Sci. USA89, 7885.Saperstein, R., et al. 1989. Biochemistry28, 5694.
Packaging
5 mg in Plastic ampoule
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :